BHAS: Beijing Hospital Atherosclerosis Study
Study Details
Study Description
Brief Summary
The Beijing Hospital Atherosclerosis Study (BHAS) is a prospective, single-center, observational cohort study performed at the Beijing Hospital in Beijing, China. Subjects enrolled in this study will be the consecutive patients undergoing coronary angiography in the hospital. Blood samples are taken immediately before the angiographic procedure. Clinical and angiographic characteristics are recorded. All patients will have routine follow-up at 6 months and 1 year postprocedure, then yearly thereafter. Follow-up includes mortality, myocardial infarction (MI), stroke, rehospitalization, coronary revascularization procedures, life styles, and medication use. The primary end point for the study will be the major adverse cardiovascular events (MACE), defined as death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization. This study has been reviewed and approved by the Ethics Committee of Beijing Hospital. All enrolled individuals will be received written notice of the intended use of their blood samples and provided written consent.
The major objectives of the BHAS Study are to (1) establish a prospective cohort and a biological sample bank in ethnic Chinese with coronary angiography, (2) identify baseline new biosignature profiles such as novel biomarkers via metabolomics approach associated with the subsequent clinical events, (3) assess the use of molecular profiles from multiple platforms (eg, genomics, proteomics, and metabolomics) integrated with readily available clinical information for improved risk classification for cardiovascular events, and (4) provide clearer understanding of underlying disease processes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Number of participants with major adverse cardiovascular events (MACE) [3 years]
MACE include death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization.
Secondary Outcome Measures
- Number of participants with other atherosclerosis events [3 years]
Other atherosclerosis events include readmission for angin and transient ischemic attack.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age >18y
-
Consent for the study
-
Primary reason for catheterization is concern for ischemic heart disease
-
Complete clinical and coronary angiogram data available
Exclusion Criteria:
-
Primary pulmonary hypertension or severe lung disease
-
Cardiac transplantation
-
Other solid organ transplant
-
Peripheral vascular intervention only
-
Right heart catheterization only
-
Advanced heart failure
-
Congenital heart disease
-
Women who are pregnant or nursing, or preparing for pregnant during the study period
-
Progressive fatal disease
-
History of alcoholism or drug abuse
-
Patients with mental illness and are being treated
-
Patients are undergoing radiotherapy or chemotherapy
-
Acute and chronic infectious diseases
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Bejing Hosptial | Beijing | Beijing | China | 100730 |
Sponsors and Collaborators
- Beijing Hospital
Investigators
- Principal Investigator: Fusui Ji, M.D., Department of Cardiology, Beijing Hospital,National Center of Gerontology
- Principal Investigator: Wenxiang Chen, M.D., The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology
- Principal Investigator: Xue Yu, M.D., Department of Cardiology, Beijing Hospital,National Center of Gerontology
Study Documents (Full-Text)
None provided.More Information
Publications
- Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008 Feb 19;51(7):701-7. doi: 10.1016/j.jacc.2007.10.034. Review.
- Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. J Am Coll Cardiol. 2016 Dec 27;68(25):2850-2870. doi: 10.1016/j.jacc.2016.09.972. Review.
- 2016BJYYEC-121-02